Standard Biotools (LAB) Cash from Investing Activities Growth (5y) (2015 - 2026)
Standard Biotools (LAB) Cash from Investing Activities Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.02 Bn | 179.73 Bn | 6.27 Bn |
| 2 | Stryker | 132.13 Bn | 129.26 Bn | 3.81 Bn |
| 3 | Medtronic | 111.43 Bn | 102.21 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.97 Bn | 67.52 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.31 Bn | 44.64 Bn | 1.29 Bn |
| 6 | Dexcom | 28.91 Bn | 27.79 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.86 Bn | 26.58 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 28.12 Bn | 27.54 Bn | - |
| 9 | Koninklijke Philips | 24.33 Bn | 21.29 Bn | 2.01 Bn |
| 10 | Standard Biotools | 302.22 Mn | -152.96 Mn | 11.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 109.97% |
| Dec 31, 2025 | -57.79% |
| Sep 30, 2025 | -20.17% |
| Jun 30, 2025 | 22.12% |
| Mar 31, 2025 | -3.48% |
| Dec 31, 2024 | 117.51% |
| Sep 30, 2024 | -46.36% |
| Jun 30, 2024 | 27.84% |
| Mar 31, 2024 | 103.15% |
| Dec 31, 2023 | -269.67% |
| Sep 30, 2023 | -129.92% |
| Jun 30, 2023 | 57.06% |
| Mar 31, 2023 | 178.01% |
| Dec 31, 2022 | 65.39% |
| Sep 30, 2022 | 88.76% |
| Jun 30, 2022 | -109.67% |
| Mar 31, 2022 | -15.43% |
| Sep 30, 2021 | -25.39% |
| Jun 30, 2021 | -101.41% |
| Mar 31, 2021 | -17.42% |